| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human MEIS1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MEIS1抗体的3篇参考文献的简要概括，涵盖不同研究方向和应用场景：
---
1. **文献名称**：*MEIS1 regulates hemangiogenic progenitor cell development through HOXA3 activation*
**作者**：Hisa T, et al.
**摘要**：该研究通过免疫组化(IHC)和Western blot实验，使用MEIS1抗体验证了其在胚胎干细胞分化过程中对血管生成的作用，并揭示MEIS1通过调控HOXA3影响造血祖细胞的发育。
2. **文献名称**：*MEIS1 is a key transcriptional regulator of prostate cancer progression*
**作者**：Hammond DE, et al.
**摘要**：通过免疫沉淀(ChIP)和MEIS1抗体结合染色质分析，研究发现MEIS1在前列腺癌中与AR(雄激素受体)协同调控致癌基因表达，促进肿瘤侵袭性生长。
3. **文献名称**：*MEIS1-mediated epigenetic reprogramming in acute myeloid leukemia*
**作者**：Huang Y, et al.
**摘要**：利用MEIS1抗体的ChIP-seq技术，揭示了MEIS1在急性髓系白血病(AML)中通过结合特定基因启动子区域，调控DNA甲基化和组蛋白修饰，驱动白血病细胞异常增殖。
---
以上文献展示了MEIS1抗体在发育生物学、癌症机制及表观遗传学中的关键应用，涉及实验技术包括Western blot、ChIP和IHC等。如需更具体信息，建议通过PubMed或Google Scholar按标题检索原文。
MEIS1 (Myeloid Ecotropic Viral Integration Site 1) antibody is a key reagent used to detect and study the MEIS1 protein, a transcription factor belonging to the TALE (Three-Amino acid Loop Extension) family. MEIS1 plays critical roles in embryonic development, hematopoiesis, and neuronal differentiation. It interacts with HOX and PBX proteins to regulate gene expression, influencing cell proliferation, differentiation, and tissue patterning. In hematopoietic stem cells, MEIS1 is essential for maintaining self-renewal capacity, while in the nervous system, it contributes to neurogenesis and dopaminergic neuron development.
Dysregulation of MEIS1 is implicated in various cancers, particularly acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL), where its overexpression often correlates with poor prognosis. It is also associated with solid tumors, such as prostate cancer and neuroblastoma. MEIS1 antibodies are widely utilized in research to investigate these mechanisms via techniques like immunohistochemistry, Western blotting, and ChIP-seq. Additionally, MEIS1 has emerged as a potential therapeutic target, driving interest in developing inhibitors.
Commercially available MEIS1 antibodies are typically validated for specificity in human, mouse, and rat models. Their applications span basic research on developmental pathways, disease biomarker studies, and drug discovery. Understanding MEIS1’s role through antibody-based assays continues to advance insights into both normal physiology and oncogenesis.
×
